Skip to main content
NCBI home page
Journal of Psychiatry & Neuroscience: JPN logoLink to Journal of Psychiatry & Neuroscience: JPN
. 1998 Sep;23(4):229–239.

The Canadian experience with risperidone for the treatment of schizophrenia: an overview.

M Iskedjian 1, M Hux 1, G J Remington 1
PMCID: PMC1188939  PMID: 9785702

Abstract

OBJECTIVE: To summarize published data to date by Canadian authors and from Canadian sources on risperidone, a novel neuroleptic indicated in the management of schizophrenia and related psychotic disorders. It was introduced in Canada in 1993. DATA SOURCES: A MEDLINE search was performed using "risperidone" as a keyword. Three Canadian journals were also searched manually. STUDY SELECTION: Articles published between January 1991 and June 1996 by Canadian authors or involving Canadian patients. DATA EXTRACTION: Retrieved articles were categorized according to data on efficacy, safety, resource use/economics and other miscellaneous aspects. Articles were abstracted and summarized. Some non-Canadian sources were used for comparison. DATA SYNTHESIS: The initial Canadian multicentre trial found resperidone (6 mg daily) to be superior to haloperidol (20 mg daily) in reducing positive and negative symptoms, with fewer extrapyramidal side effects (EPS). Various case reports have extended both the clinical use and safety profile of risperidone, while neuro-imaging studies have tried to clarify its mechanism of action. Economic studies suggest substantial cost benefits due to prevention of hospitalization as well as improvement in quality of life. CONCLUSIONS: Canadian research has contributed considerably to the current knowledge regarding risperidone. Future studies, both controlled and naturalistic, will need to focus on comparisons with the various new compounds now available.

Full text

PDF
229

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Addington D. E., Jones B., Bloom D., Chouinard G., Remington G., Albright P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther. 1993 Sep-Oct;15(5):917–926. [PubMed] [Google Scholar]
  2. Addington D. E., Toews J. A., Addington J. M. Risperidone and tardive dyskinesia: a case report. J Clin Psychiatry. 1995 Oct;56(10):484–485. [PubMed] [Google Scholar]
  3. Addington D. Risperidone: integrating research and practice. Br J Hosp Med. 1994 Sep 7;52(5):223–224. [PubMed] [Google Scholar]
  4. Appleby L., Desai P. N., Luchins D. J., Gibbons R. D., Hedeker D. R. Length of stay and recidivism in schizophrenia: a study of public psychiatric hospital patients. Am J Psychiatry. 1993 Jan;150(1):72–76. doi: 10.1176/ajp.150.1.72. [DOI] [PubMed] [Google Scholar]
  5. Beasley C. M., Jr, Tollefson G. D., Tran P. V. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry. 1997;58 (Suppl 10):7–12. [PubMed] [Google Scholar]
  6. Bezchlibnyk-Butler K. Z., Remington G. J. Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms. Can J Psychiatry. 1994 Mar;39(2):74–84. doi: 10.1177/070674379403900203. [DOI] [PubMed] [Google Scholar]
  7. Bland R. C. Long term mental illness in Canada: an epidemiological perspective on schizophrenia and affective disorders. Can J Psychiatry. 1984 Apr;29(3):242–246. doi: 10.1177/070674378402900310. [DOI] [PubMed] [Google Scholar]
  8. Bondolfi G., Baumann P., Dufour H. Treatment-resistant schizophrenia: clinical experience with new antipsychotics. Eur Neuropsychopharmacol. 1996;6 (Suppl 2):S21–S25. doi: 10.1016/0924-977x(96)00012-0. [DOI] [PubMed] [Google Scholar]
  9. Brenner H. D., Dencker S. J., Goldstein M. J., Hubbard J. W., Keegan D. L., Kruger G., Kulhanek F., Liberman R. P., Malm U., Midha K. K. Defining treatment refractoriness in schizophrenia. Schizophr Bull. 1990;16(4):551–561. doi: 10.1093/schbul/16.4.551. [DOI] [PubMed] [Google Scholar]
  10. Casey D. E. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 1989;99 (Suppl):S47–S53. doi: 10.1007/BF00442559. [DOI] [PubMed] [Google Scholar]
  11. Chong S. A., Tan C. H., Lee H. S. Hoarding and clozapine-risperidone combination. Can J Psychiatry. 1996 Jun;41(5):315–316. doi: 10.1177/070674379604100511. [DOI] [PubMed] [Google Scholar]
  12. Chouinard G., Albright P. S. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol. 1997 Aug;17(4):298–307. doi: 10.1097/00004714-199708000-00010. [DOI] [PubMed] [Google Scholar]
  13. Chouinard G., Arnott W. Clinical review of risperidone. Can J Psychiatry. 1993 Sep;38 (Suppl 3):S89–S95. [PubMed] [Google Scholar]
  14. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol. 1995 Feb;15(1 Suppl 1):36S–44S. doi: 10.1097/00004714-199502001-00007. [DOI] [PubMed] [Google Scholar]
  15. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G. W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993 Feb;13(1):25–40. [PubMed] [Google Scholar]
  16. Chouinard G., Vainer J. L., Bélanger M. C., Turnier L., Beaudry P., Roy J. Y., Miller R. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry. 1994 Nov;18(7):1129–1141. doi: 10.1016/0278-5846(94)90116-3. [DOI] [PubMed] [Google Scholar]
  17. Clarke D. E., Yaeger S. F. Addressing emerging social needs of patients treated with new neuroleptics. J Psychosoc Nurs Ment Health Serv. 1994 Nov;32(11):19–22. doi: 10.3928/0279-3695-19941101-11. [DOI] [PubMed] [Google Scholar]
  18. Collins E. J., Hogan T. P., Awad A. G. The pharmacoepidemiology of treatment-refractory schizophrenia. Can J Psychiatry. 1992 Apr;37(3):192–195. doi: 10.1177/070674379203700309. [DOI] [PubMed] [Google Scholar]
  19. Curtis V. A., Kerwin R. W. A risk-benefit assessment of risperidone in schizophrenia. Drug Saf. 1995 Feb;12(2):139–145. doi: 10.2165/00002018-199512020-00006. [DOI] [PubMed] [Google Scholar]
  20. Dickson R. A., Dalby J. T., Williams R., Edwards A. L. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry. 1995 Jul;152(7):1102–1103. doi: 10.1176/ajp.152.7.1102b. [DOI] [PubMed] [Google Scholar]
  21. Dickson R., Williams R., Dalby J. T. Dystonic reaction and relapse with clozapine discontinuation and risperidone intiation. Can J Psychiatry. 1994 Apr;39(3):184–184. doi: 10.1177/070674379403900318. [DOI] [PubMed] [Google Scholar]
  22. Emes C. E., Millson R. C. Risperidone-induced priapism. Can J Psychiatry. 1994 Jun;39(5):315–316. doi: 10.1177/070674379403900523. [DOI] [PubMed] [Google Scholar]
  23. Ereshefsky L., Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry. 1993 Sep;38 (Suppl 3):S80–S88. [PubMed] [Google Scholar]
  24. Glazer W. M., Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry. 1996 Aug;57(8):337–345. [PubMed] [Google Scholar]
  25. He H., Richardson J. S. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol. 1995 Mar;10(1):19–30. doi: 10.1097/00004850-199503000-00003. [DOI] [PubMed] [Google Scholar]
  26. Jeffries J. J. Ethical issues in drug selection for schizophrenia. Can J Psychiatry. 1993 Sep;38 (Suppl 3):S70–S74. [PubMed] [Google Scholar]
  27. Jones B. D., Purdon S. E., Labelle A., Finlayson R. Risperidone treatment for severe negative symptoms. Can J Psychiatry. 1994 Aug;39(6):381–381. doi: 10.1177/070674379403900616. [DOI] [PubMed] [Google Scholar]
  28. Jones B. Schizophrenia: into the next millennium. Can J Psychiatry. 1993 Sep;38 (Suppl 3):S67–S69. [PubMed] [Google Scholar]
  29. Kane J. M. Treatment-resistant schizophrenic patients. J Clin Psychiatry. 1996;57 (Suppl 9):35–40. [PubMed] [Google Scholar]
  30. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988 Sep;45(9):789–796. doi: 10.1001/archpsyc.1988.01800330013001. [DOI] [PubMed] [Google Scholar]
  31. Kapur S., Remington G., Jones C., Wilson A., DaSilva J., Houle S., Zipursky R. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry. 1996 Jul;153(7):948–950. doi: 10.1176/ajp.153.7.948. [DOI] [PubMed] [Google Scholar]
  32. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996 Apr;153(4):466–476. doi: 10.1176/ajp.153.4.466. [DOI] [PubMed] [Google Scholar]
  33. Kapur S., Remington G., Zipursky R. B., Wilson A. A., Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 1995;57(10):PL103–PL107. doi: 10.1016/0024-3205(95)02037-j. [DOI] [PubMed] [Google Scholar]
  34. Keegan D. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug. Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S46–S52. [PubMed] [Google Scholar]
  35. Klieser E., Lehmann E., Kinzler E., Wurthmann C., Heinrich K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol. 1995 Feb;15(1 Suppl 1):45S–51S. doi: 10.1097/00004714-199502001-00008. [DOI] [PubMed] [Google Scholar]
  36. Kopala L. C., Fredrikson D., Good K. P., Honer W. G. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone. Biol Psychiatry. 1996 Feb 15;39(4):296–298. doi: 10.1016/0006-3223(95)00500-5. [DOI] [PubMed] [Google Scholar]
  37. Kopala L. C., Honer W. G. Schizophrenia and severe tardive dyskinesia responsive to risperidone. J Clin Psychopharmacol. 1994 Dec;14(6):430–431. [PubMed] [Google Scholar]
  38. Kopala L., Honer W. G. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry. 1994 Nov;151(11):1714–1715. doi: 10.1176/ajp.151.11.1714a. [DOI] [PubMed] [Google Scholar]
  39. Landry P. Effect of risperidone on polydipsia and hyponatremia in schizophrenia. Can J Psychiatry. 1995 Nov;40(9):566–567. doi: 10.1177/070674379504000914. [DOI] [PubMed] [Google Scholar]
  40. Laupacis A., Feeny D., Detsky A. S., Tugwell P. X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992 Feb 15;146(4):473–481. [PMC free article] [PubMed] [Google Scholar]
  41. Lehmann H. E., Ban T. A. The history of the psychopharmacology of schizophrenia. Can J Psychiatry. 1997 Mar;42(2):152–162. doi: 10.1177/070674379704200205. [DOI] [PubMed] [Google Scholar]
  42. MacEwan G. W. New antipsychotic medications: do research results relate to clinical practice? Can J Psychiatry. 1993 Sep;38 (Suppl 3):S75–S79. [PubMed] [Google Scholar]
  43. Marder S. R., Meibach R. C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994 Jun;151(6):825–835. doi: 10.1176/ajp.151.6.825. [DOI] [PubMed] [Google Scholar]
  44. McEvoy J. P. Efficacy of risperidone on positive features of schizophrenia. J Clin Psychiatry. 1994 May;55 (Suppl):18–21. [PubMed] [Google Scholar]
  45. Meltzer H. Y., Bastani B., Kwon K. Y., Ramirez L. F., Burnett S., Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl) 1989;99 (Suppl):S68–S72. doi: 10.1007/BF00442563. [DOI] [PubMed] [Google Scholar]
  46. Mercier C., Renaud C., King S. A thirty-year retrospective study of hospitalization among severely mentally ill patients. Can J Psychiatry. 1994 Mar;39(2):95–102. doi: 10.1177/070674379403900206. [DOI] [PubMed] [Google Scholar]
  47. Meterissian G. B. Risperidone-induced neuroleptic malignant syndrome: a case report and review. Can J Psychiatry. 1996 Feb;41(1):52–54. doi: 10.1177/070674379604100112. [DOI] [PubMed] [Google Scholar]
  48. Miller R., Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry. 1993 Nov 15;34(10):713–738. doi: 10.1016/0006-3223(93)90044-e. [DOI] [PubMed] [Google Scholar]
  49. Musser W. S., Kirisci L. Critique of the Canadian Multicenter Placebo-Controlled Study of Risperidone and Haloperidol. J Clin Psychopharmacol. 1995 Jun;15(3):226–230. doi: 10.1097/00004714-199506000-00016. [DOI] [PubMed] [Google Scholar]
  50. Möller H. J., Müller H., Borison R. L., Schooler N. R., Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci. 1995;245(1):45–49. doi: 10.1007/BF02191543. [DOI] [PubMed] [Google Scholar]
  51. Möller H. J., Pelzer E., Kissling W., Riehl T., Wernicke T. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. Pharmacopsychiatry. 1991 Nov;24(6):185–189. doi: 10.1055/s-2007-1014467. [DOI] [PubMed] [Google Scholar]
  52. Naranjo C. A., Herrmann N., Mittmann N., Bremner K. E. Recent advances in geriatric psychopharmacology. Drugs Aging. 1995 Sep;7(3):184–202. doi: 10.2165/00002512-199507030-00004. [DOI] [PubMed] [Google Scholar]
  53. O'Croinin F., Zibin T., Holt L. Re: Hypomania associated with risperidone. Can J Psychiatry. 1995 Feb;40(1):51–51. doi: 10.1177/070674379504000117. [DOI] [PubMed] [Google Scholar]
  54. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995 Jun;166(6):712–733. doi: 10.1192/bjp.166.6.712. [DOI] [PubMed] [Google Scholar]
  55. Purdon S. E., Lit W., Labelle A., Jones B. D. Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry. 1994 Sep;39(7):400–405. doi: 10.1177/070674379403900703. [DOI] [PubMed] [Google Scholar]
  56. Randhawa J., Riley R. Mental health statistics, 1982-83 to 1993-94. Health Rep. 1996 Spring;7(4):55-61, 59-65. [PubMed] [Google Scholar]
  57. Remington G. J. Clinical considerations in the use of risperidone. Can J Psychiatry. 1993 Sep;38 (Suppl 3):S96–100. [PubMed] [Google Scholar]
  58. Remington G. J. Novel neuroleptics in schizophrenia: theory and clinical relevance. Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S43–S45. [PubMed] [Google Scholar]
  59. Remington G. J. The long-term treatment of schizophrenia. Can J Psychiatry. 1995 Apr;40(3 Suppl 1):S3–S4. [PubMed] [Google Scholar]
  60. Remington G., Adams M. Risperidone and obsessive-compulsive symptoms. J Clin Psychopharmacol. 1994 Oct;14(5):358–359. doi: 10.1097/00004714-199410000-00014. [DOI] [PubMed] [Google Scholar]
  61. Remington G. Understanding schizophrenia: the impact of novel antipsychotics. Can J Psychiatry. 1995 Sep;40(7 Suppl 2):S29–S32. doi: 10.1177/070674379504007s01. [DOI] [PubMed] [Google Scholar]
  62. Robertson G. S., Matsumura H., Fibiger H. C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther. 1994 Nov;271(2):1058–1066. [PubMed] [Google Scholar]
  63. Sajatovic M., Ramirez L. F., Vernon L., Brescan D., Simon M., Jurjus G. Outcome of risperidone therapy in elderly patients with chronic psychosis. Int J Psychiatry Med. 1996;26(3):309–317. doi: 10.2190/NY2L-6YF4-B1DA-W6DX. [DOI] [PubMed] [Google Scholar]
  64. Schizophrenia research. Psychopharmacology. J Psychiatry Neurosci. 1994 Nov;19(5 Suppl 1):29–33. [PMC free article] [PubMed] [Google Scholar]
  65. Seeman P. Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiatr Scand Suppl. 1990;358:14–20. doi: 10.1111/j.1600-0447.1990.tb05280.x. [DOI] [PubMed] [Google Scholar]
  66. Shriqui C. L. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen. Can J Psychiatry. 1995 Sep;40(7 Suppl 2):S38–S48. doi: 10.1177/070674379504007s03. [DOI] [PubMed] [Google Scholar]
  67. Sigmundson H. K. Pharmacotherapy of schizophrenia: a review. Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S70–S75. [PubMed] [Google Scholar]
  68. Stip E., Tourjman V., Lew V., Fabian J., Cormier H., Landry P., Lalonde P., Cournoyer J. "Awakenings" effect with risperidone. Am J Psychiatry. 1995 Dec;152(12):1833–1833. doi: 10.1176/ajp.152.12.1833a. [DOI] [PubMed] [Google Scholar]
  69. Takhar J., Manchanda R. Acute dystonic reaction with risperidone. Can J Psychiatry. 1996 Feb;41(1):61–62. [PubMed] [Google Scholar]
  70. Tran P. V., Hamilton S. H., Kuntz A. J., Potvin J. H., Andersen S. W., Beasley C., Jr, Tollefson G. D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997 Oct;17(5):407–418. doi: 10.1097/00004714-199710000-00010. [DOI] [PubMed] [Google Scholar]
  71. Villeneuve A. Pathophysiology and treatment of negative symptoms. Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S53–S58. [PubMed] [Google Scholar]
  72. Wasylenki D. A. The cost of schizophrenia. Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S65–S69. [PubMed] [Google Scholar]
  73. Williams R., Dickson R. A. Economics of schizophrenia. Can J Psychiatry. 1995 Sep;40(7 Suppl 2):S60–S67. doi: 10.1177/070674379504007s06. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Science Publishing

RESOURCES